Jul 27, 2020
Acurx Pharmaceuticals Phase 2 Clinical Trial of ibezapolstat Is In Progress
Acurx Pharmaceuticals Phase 2 Clinical Trial of ibezapolstat Is In Progress
Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical stage biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced on July 27th, 2020 that a Phase 2 clinical trial of the Company’s lead antibiotic product candidate is in progress. In this trial, orally-administered ibezapolstat given 450 mg twice daily for 10 days…
View On WordPress